pas-004
pas-004: developed by 1 company · 2 clinical trials tracked.
pas-004 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could pas-004 → KTTA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Pasithea Therapeutics Corp. (KTTA) RAS Mutation; NF1 Mutation | Phase 1 |
Clinical Trials (2)
A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas
Primary endpoint: Part A: To evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycle
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition
Primary endpoint: Evaluation of dose limiting toxicities (DLTs)
Frequently asked questions
Who is developing pas-004?
pas-004 is being developed by Pasithea Therapeutics Corp..
How many clinical trials involve pas-004?
BioSniper tracks 2 clinical trials involving pas-004.